The Laboratory of Retinal Cell and Molecular Biology (LRCMB) plans, conducts, and directs basic research in normal and abnormal functioning of the retina, other ocular tissues, and in retinal diseases, particularly those of a genetic nature. Visual process mechanisms are emphasized as well as the function of neural, glial, and pigment epithelial cells.
The Laboratory of Retinal Cell and Molecular Biology Office of the Chief includes the following staff:
|T. Michael Redmond, Ph.D.||Chief of LRCMBemail@example.com||(301) 496-0439|
|Julia Goldson||Administrative Lab Managerfirstname.lastname@example.org||(301) 496-9025|
|Cynthia J. Jaworski, Ph.D.||Molecular Informatics Specialist||Jaworskic@nei.nih.gov||(301) 496-1396|
The Laboratory of Retinal Cell and Molecular Biology comprises the following sections:
Section Chief: T. Michael Redmond, Ph.D. email@example.com
We study mechanisms of vitamin A and lipid metabolism, and signaling and regulation processes, central to vision and function of the retina and retinal pigment epithelium (RPE) to better understand and treat blinding diseases.
Section Chief: S. Patricia Becerra, Ph.D. firstname.lastname@example.org
The interests of our Section are in the area of protein structure as it relates to function, with a focus on the interactions of components involved in cell differentiation survival and maintenance. Our research has applied these interests to systems in the retina.
Section Chief: Stanislav Tomarev, Ph.D. email@example.com
Our Section conducts basic research on glaucoma. We study genes, proteins and signaling pathways that might be essential for RGC and optic nerve development, function, survival, and regeneration. Our interests are concentrated on early changes in the retina and the optic nerve during the course of glaucoma.
Unit Chief: Wai T. Wong, M.D., Ph.D. firstname.lastname@example.org
The mission of our unit (UNGIRD) is to explore and understand the fundamental biological mechanisms underlying retinal diseases and translate these findings into proof-of-concept clinical studies to discover new therapies.